ELVN
Enliven Therapeutics Inc

1,275
Mkt Cap
$1.59B
Volume
436,317.00
52W High
$30.22
52W Low
$13.30
PE Ratio
-14.48
ELVN Fundamentals
Price
$26.72
Prev Close
$27.16
Open
$27.25
50D MA
$22.24
Beta
1.46
Avg. Volume
1.62M
EPS (Annual)
-$1.89
P/B
3.33
Rev/Employee
$0.00
$745.64
Loading...
Loading...
News
all
press releases
Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) Insider Sells 5,000 Shares of Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 5,000 shares of the business's stock in a transaction that occurred on Friday, February 6th. The stock was...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Candriam S.C.A. Raises Stock Position in Enliven Therapeutics, Inc. $ELVN
Candriam S.C.A. grew its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 46.3% during the 3rd quarter, according to its most recent filing with the Securities and...
MarketBeat·5d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $145,200.00 in Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 5,000 shares of the company's stock in a transaction dated Friday, February 6th. The stock was sold at an...
MarketBeat·5d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Sets New 1-Year High - What's Next?
Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High - Here's What Happened...
MarketBeat·9d ago
News Placeholder
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k
Key PointsEnliven Therapeutics' Chief Scientific Officer sold 20,000 indirect shares for a total of approximately $535,100 on Jan. 20, 2026, at a weighted average price of around $26.75 per share...
Nasdaq News: Markets·15d ago
News Placeholder
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of "Moderate Buy" by Brokerages
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five analysts that are presently covering the stock, Marketbeat...
MarketBeat·20d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Director Sells 1,230 Shares
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard Heyman sold 1,230 shares of the business's stock in a transaction dated Tuesday, January 20th. The stock was sold at an...
MarketBeat·24d ago
News Placeholder
Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 20,000 shares of the company's stock in a transaction on Tuesday, January 20th. The stock was sold at an...
MarketBeat·24d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 7.4% - Should You Buy?
Enliven Therapeutics (NASDAQ:ELVN) Trading Up 7.4% - Should You Buy...
MarketBeat·1mo ago
News Placeholder
Joseph Lyssikatos Sells 41,302 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 41,302 shares of the business's stock in a transaction that occurred on Thursday, January 8th. The shares...
MarketBeat·1mo ago
<
1
2
...
>

Latest ELVN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.